P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study
Authors
Keywords
-
Journal
MOLECULES
Volume 25, Issue 1, Pages 5
Publisher
MDPI AG
Online
2019-12-23
DOI
10.3390/molecules25010005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of silkworm peptide on inducting M1 type polarization and Th1 activation via TLR2-induced MyD88-dependent pathway
- (2019) Guanglai Zhu et al. Food Science & Nutrition
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling
- (2018) Luiz Gustavo de Almeida Chuffa et al. Journal of Ovarian Research
- The role of sex hormones and steroid receptors on female reproductive cancers
- (2017) Luiz Gustavo de Almeida Chuffa et al. STEROIDS
- A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer
- (2016) Mark H. Ebell et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier
- (2016) Patrick Vianna Garcia et al. BMC CANCER
- Minireview: Regulatory T Cells and Ovarian Cancer
- (2016) Manindra Singh et al. IMMUNOLOGICAL INVESTIGATIONS
- Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer
- (2016) Courtney A. Cohen et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target
- (2016) M. Obayed Ullah et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Silencing MARCH1 suppresses proliferation, migration and invasion of ovarian cancer SKOV3 cells via downregulation of NF-κB and Wnt/β-catenin pathways
- (2016) Ying Meng et al. ONCOLOGY REPORTS
- TH9 cells in anti-tumor immunity
- (2016) Thaiz Rivera Vargas et al. Seminars in Immunopathology
- The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins
- (2016) Zheng Li et al. TUMOR BIOLOGY
- Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein
- (2016) Alexandria B. Tino et al. Journal of Ovarian Research
- Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer
- (2015) Luiz Gustavo A Chuffa et al. BMC CANCER
- The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy
- (2015) E. Zsiros et al. CLINICAL CANCER RESEARCH
- Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells
- (2015) Snehal M. Gaikwad et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88
- (2015) Yueping Zhan et al. Journal of Ovarian Research
- Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy
- (2014) Jungsun Park et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer
- (2014) Charles J. d'Adhemar et al. PLoS One
- Tumor-Associated Macrophages Contribute to Tumor Progression in Ovarian Cancer
- (2014) Emily K. Colvin Frontiers in Oncology
- Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?
- (2013) Giuseppe Bronte et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer
- (2013) Vincent Lavoué et al. Journal of Translational Medicine
- Characterization of Chemically Induced Ovarian Carcinomas in an Ethanol-Preferring Rat Model: Influence of Long-Term Melatonin Treatment
- (2013) Luiz Gustavo A. Chuffa et al. PLoS One
- Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells
- (2012) Anna Fialová et al. INTERNATIONAL JOURNAL OF CANCER
- Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers
- (2012) Ki Kim et al. World Journal of Surgical Oncology
- Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer
- (2012) Wagner J Fávaro et al. Infectious Agents and Cancer
- Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells
- (2009) A. C. Wang et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer
- (2009) M Szajnik et al. ONCOGENE
- Role of Chemokine Network in the Development and Progression of Ovarian Cancer: A Potential Novel Pharmacological Target
- (2009) Federica Barbieri et al. Journal of Oncology
- The inflammatory chemokines CCL2 and CCL5 in breast cancer
- (2008) Gali Soria et al. CANCER LETTERS
- Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells
- (2008) R Chen et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started